Bizzell CEO Appointed to CSAP National Advisory Council
In recognition of his extensive expertise in substance abuse prevention and treatment, Anton Bizzell, M.D., CEO of The Bizzell Group (Bizzell), has been appointed by the Secretary of the U.S. Department of Health and Human Services (HHS) to serve on the Substance Abuse and Mental Health Services Administration’s (SAMHSA) Center for Substance Abuse Prevention (CSAP) National Advisory Council. Dr. Bizzell’s appointment is effective through November 2018.
CSAP leads the development of national substance abuse prevention policies and programming, promotes the adoption of proven, science-based substance abuse prevention approaches and helps states and communities build their capacity to implement these approaches. As a member of the CSAP National Advisory Council, Dr. Bizzell will support this mission by making recommendations on agency and center activities and policies, in addition to reviewing grant and cooperative agreement submissions. “It’s a great honor and responsibility to work at a national level to help states and communities find proven and practical ways to prevent substance abuse and reduce the impact this disease has on individuals, families and communities,” said Dr. Bizzell.
Since earning his Doctorate in Medicine from the University of Virginia, Dr. Bizzell has spent the majority of his career working to improve access and quality of care issues for people experiencing substance abuse, mental illness or complicating health issues. He has more than 20 years of combined clinical, research, health services, policy and management experiences with various private and public organizations, including his service as a Medical Officer at both the National Institute on Alcohol Abuse and Alcoholism, NIH, and the Center for Substance Abuse Treatment, SAMHSA. Dr. Bizzell has also provided leadership to projects of national significance including CSAP’s Prevention Fellowship Program, SAMHSA’s Federal Drug Free Workplace Technical Support contract, and SAMHSA’s Prescription Drug Misuse and Abuse project.
